Hematology · Oncology · 3 h ago
Review examines long-term CAR T-cell outcomes in large B-cell lymphoma
A narrative review summarizes evidence for CAR T-cell therapy in relapsed or refractory large B-cell lymphoma (LBCL), including long-term follow-up from the phase 3 ZUMA-7 and TRANSFORM trials. The authors describe survival-curve plateaus around two years and remissions sustained to five years, while noting that further follow-up is needed.
- Narrative review of CAR T-cell therapy in relapsed or refractory LBCL
- Includes long-term data from ZUMA-7 and TRANSFORM
- Survival curves plateau around two years; remissions persist to five years
- Authors call for continued follow-up and broader analyses
About 30%–40% of patients with large B-cell lymphoma relapse after or do not respond to first-line chemoimmunotherapy. This narrative review discusses CAR T-cell therapy as a curative-intent option for relapsed or refractory disease, focusing on evidence from phase 3 ZUMA-7 and TRANSFORM and other CAR T-cell studies. Treatment choice in second line can depend on whether disease is refractory or relapses early versus later, as well as patient eligibility.
The review reports that long-term follow-up from ZUMA-7 and TRANSFORM shows plateaus in Kaplan–Meier survival curves at around two years, with remissions continuing to five years. The authors interpret these findings as evidence of the potential for durable, possibly curative outcomes with CAR T-cell therapy. They also emphasize the need for continued follow-up and broader analyses. This is a narrative synthesis of existing studies, not a new trial; the abstract provides no pooled effect estimates or detailed subgroup results.
In practice
For patients with relapsed or refractory LBCL who are eligible for second-line CAR T-cell therapy, long-term follow-up summarized in this review supports the possibility of durable remission, including among patients with refractory or early-relapsing disease. The findings may inform discussion of treatment options, but this is a narrative review of existing trials rather than new comparative evidence. The reported survival-curve plateaus and remissions through five years do not establish cure for an individual patient; continued follow-up and broader analyses are needed.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
HemaSphere: Chimeric antigen receptor T‐cell therapy as a cure for large B‐cell lymphoma ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.